Ryght AI has announced a strategic collaboration with QPS Holdings for optimising clinical trial processes globally.
Under the agreement, QPS, a full-service contract research organisation (CRO), has selected Ryght AI as its exclusive artificial intelligence (AI) partner for optimising and automating the trials.
Go deeper with GlobalData
By integrating Ryght AI’s technology with QPS’s experience and global network, the collaboration aims to streamline clinical trial workflows and is set to tackle challenges such as inefficient communications, cumbersome site selection, and operational delays.
QPS is set to integrate its 750 research sites network across 17 countries into the Ryght Research Network, enhancing its reach and capabilities.
By utilising generative AI capabilities to deliver real-time insights, the Ryght Research Network claims to enable data-driven decisions while maintaining data security.
Ryght AI CEO Simon Arkell said: “We are thrilled to join forces with QPS, one of the most innovative CROs in the world. Their network of 750 research sites will gain a tremendous advantage through our AI-powered solutions. This collaboration exemplifies our shared commitment to accelerating clinical trials and improving patient outcomes globally.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataWith the automation of site selection, patient referrals, and feasibility assessments, the collaboration aims to simplify the management of trials for research sites and accelerate optimal site as well as participant selection for sponsors.
It will also expedite the timelines of the clinical trials, minimise administrative-related burdens, and rapidly offer therapies to patients.
QPS Clinical Research global head and executive vice-president Derek Grimes said: “Ryght AI’s unique and powerful platform, coupled with their verticalised AI applications, will be truly transformative in providing real-time communications between QPS and our global network of sites.
“This will streamline clinical trials from site selection to activation, enrolment, and workflows, ultimately speeding up time to market for our biopharma clients. We’re excited about the possibilities of this partnership to enhance our services and drive innovation in clinical research.”
Ryght AI specialises in providing real-time generative AI solutions to the clinical research industry.
